Eli Lilly, the pharmaceutical company developing retatrutide, is conducting multiple large-scale trials evaluating its efficacy for obesity, type 2 diabetes, and metabolic-associated fatty liver disease
[15] Mechanism of action [edit] Upon binding to its ligand GLP-1, the GLP-1 receptor activates intracellular signaling pathways that regulate insulin secretion, glucose metabolism, and satiety
Heres how often the most common GI side effects showed up in the study: What else did the data tell us
Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinsons disease: an open label, phase I trial
Kidney health protection GLP-1s have shown promising results in protecting kidney function, especially in patients with type 2 diabetes and chronic kidney disease